Market capitalization | $59.20m |
Enterprise Value | $-27.24m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.43 |
EV/Sales (TTM) EV/Sales | -4.23 |
P/S ratio (TTM) P/S ratio | 9.19 |
P/B ratio (TTM) P/B ratio | 0.61 |
Revenue growth (TTM) Revenue growth | 382.75% |
Revenue (TTM) Revenue | $6.44m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
5 Analysts have issued a Shattuck Labs Inc forecast:
5 Analysts have issued a Shattuck Labs Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 6.44 6.44 |
384%
384%
|
|
Gross Profit | 2.57 2.57 |
186%
186%
|
|
EBITDA | -76 -76 |
20%
20%
|
EBIT (Operating Income) EBIT | -80 -80 |
20%
20%
|
Net Profit | -74 -74 |
22%
22%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Shattuck Labs, Inc. engages in the research and development of Agonist Redirected Checkpoint (ARC) platform. It develops a novel class of biologic medicines, capable of multifunctional activity, with potential applications in oncology and autoimmune diseases. The company was founded by Josiah C. Hornblower and Taylor Schreiber in 2016 and is headquartered in Austin, TX.
Head office | United States |
CEO | Taylor Schreiber |
Employees | 75 |
Founded | 2016 |
Website | www.shattucklabs.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.